Platform Clinical Study for Conquering Scleroderma: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2b Platform Clinical Study to Evaluate the Safety and Efficacy of Investigational Products in Participants With Interstitial Lung Disease Secondary to Systemic Sclerosis

Protocol No
RHEU-SRF-CONQUEST
Staff Member
Mary Ellen Csuka
Phase
II
Summary

The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end of the treatment period at Week 52 in lung capacity in participants with Interstitial Lung Disease Secondary to Systemic Sclerosis.
Objective
Platform Clinical Study for Conquering Scleroderma
Study Sites
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Rheumatology, Systemic Sclerosis
ClinicalTrials.gov
https://www.clinicaltrials.gov/study/NCT06195072